# CYP2C8

## Overview
CYP2C8 is a gene that encodes the enzyme cytochrome P450 family 2 subfamily C member 8, a critical component of the cytochrome P450 superfamily. This enzyme is primarily involved in the metabolism of a wide array of endogenous and exogenous compounds, including drugs and fatty acids. As a monooxygenase, CYP2C8 plays a pivotal role in the oxidative metabolism of therapeutic agents such as paclitaxel and ibuprofen, as well as in the conversion of arachidonic acid to epoxyeicosatrienoic acids, which are important for various physiological processes (Backman2015Role). The enzyme's activity is modulated by interactions with other proteins and is subject to genetic polymorphisms that can significantly impact drug metabolism and efficacy, highlighting its relevance in pharmacogenomics and personalized medicine (Lam2016Genotypes; Kandel2014Role).

## Structure
The CYP2C8 protein is a member of the cytochrome P450 superfamily, which plays a crucial role in drug metabolism. The primary structure of CYP2C8 consists of a sequence of amino acids that form the basis for its complex structure. The secondary structure includes alpha-helices and beta-sheets, which contribute to the protein's stability and function (Jiang2010Structural). The tertiary structure of CYP2C8 is characterized by a compact, globular shape with a heme-binding domain, essential for its enzymatic activity (Jiang2010Structural).

CYP2C8 has a large active site with a bifurcated Y-shaped geometry, allowing it to accommodate various substrates, including retinoic acids (Foti2016Comparison). The active site is larger than that of other CYP2Cs, facilitating different substrate orientations and interactions with specific amino acid residues like Arg241 and Phe205 (Melet2004Analysis). These residues are involved in substrate binding and recognition, influencing the enzyme's specificity and catalytic properties (Melet2004Analysis).

Post-translational modifications, such as phosphorylation and glycosylation, may occur, although specific details are not provided in the context. The protein may also form complexes with other proteins, although quaternary structure details are less common.

## Function
CYP2C8 is a crucial enzyme in the cytochrome P450 family, primarily involved in the metabolism of both endogenous and exogenous compounds. It plays a significant role in the conversion of arachidonic acid to epoxyeicosatrienoic acids (EETs), which are vital for regulating physiological processes such as vascular function, blood pressure, pancreatic hormone secretion, and platelet aggregation (Backman2015Role). CYP2C8 is also involved in the metabolism of all-trans-retinoic acid, a form of vitamin A essential for gene transcription, cell division, and differentiation, although its role is less significant compared to other enzymes like CYP26A1 and CYP3A4 (Backman2015Role).

In addition to its role in endogenous metabolism, CYP2C8 is highly active in drug metabolism, processing a wide range of therapeutic drugs including paclitaxel, diazepam, ibuprofen, and montelukast (Backman2015Role). The enzyme is expressed in the liver and various extrahepatic tissues such as the adrenal gland, brain, heart, kidney, and lung, indicating its widespread role in maintaining cellular homeostasis and protecting against toxic substances (Backman2015Role). Its activity is regulated by nuclear receptors, including the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which influence its expression in response to various stimuli (Ferguson2005Human).

## Clinical Significance
Mutations and polymorphisms in the CYP2C8 gene have significant clinical implications, particularly in drug metabolism and associated toxicities. The CYP2C8*3 allele is linked to altered pharmacokinetics of several drugs, including repaglinide, rosiglitazone, pioglitazone, and paclitaxel. This allele results in reduced plasma concentrations of repaglinide and increased clearance of thiazolidinediones, affecting their therapeutic efficacy in type 2 diabetes patients (Backman2015Role). It is also associated with an increased risk of paclitaxel-induced neurotoxicity due to decreased drug clearance, leading to higher exposure (Dai2001Polymorphisms; Lam2016Genotypes).

In liver transplant patients, the CYP2C8*3 allele is associated with an increased risk of calcineurin inhibitor-induced chronic kidney disease, particularly with tacrolimus treatment. This is attributed to reduced formation of vasodilatory epoxyeicosatrienoic acids, which are crucial for kidney function (Smith2008Role). Additionally, the CYP2C8*3 variant has been linked to increased metabolic clearance of cerivastatin, contributing to the risk of rhabdomyolysis, a condition characterized by muscle breakdown (Kaspera2010Cerivastatin). These genetic variations underscore the importance of CYP2C8 in personalized medicine, influencing drug efficacy and safety profiles.

## Interactions
CYP2C8 interacts with several proteins that influence its metabolic activity. One significant interaction is with cytochrome P450 reductase (CPR), which is essential for electron transfer during the enzyme's catalytic cycle. This interaction is characterized by a high affinity, with dissociation constants ranging from 5 to 110 nM, indicating strong binding interactions (Kandel2014Role). The presence of substrates and inhibitors can modulate these interactions, affecting the electron transfer process crucial for drug metabolism (Kandel2014Role).

CYP2C8 also interacts with cytochrome b5, which acts as an activator of P450-mediated drug oxidations. This interaction enhances the metabolic activity of CYP2C8, particularly in its variant form CYP2C8.3, which shows higher in vitro activity compared to the wild-type CYP2C8.1. The increased activity is due to a higher affinity of CYP2C8.3 for cytochrome b5, resulting in decreased reaction uncoupling (Kaspera2011Drug).

Additionally, CYP2C8 interacts with progesterone receptor membrane component 1 (PGRMC1), which generally down-regulates CYP activities, including CYP2C8. This down-regulation can be counteracted by increased expression of CPR, suggesting a competitive interaction between PGRMC1 and CYP2C8 for binding to CPR (Kandel2014Role). These interactions highlight the complex regulatory mechanisms influencing CYP2C8's role in drug metabolism.


## References


[1. (Kaspera2011Drug) Rüdiger Kaspera, Suresh B. Naraharisetti, Eric A. Evangelista, Kristin D. Marciante, Bruce M. Psaty, and Rheem A. Totah. Drug metabolism by cyp2c8.3 is determined by substrate dependent interactions with cytochrome p450 reductase and cytochrome b5. Biochemical Pharmacology, 82(6):681–691, September 2011. URL: http://dx.doi.org/10.1016/j.bcp.2011.06.027, doi:10.1016/j.bcp.2011.06.027. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2011.06.027)

[2. (Lam2016Genotypes) Siu W Lam, Charlotte N Frederiks, Tahar van der Straaten, Aafke H Honkoop, Henk-Jan Guchelaar, and Epie Boven. Genotypes of cyp2c8 and fgd4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. British Journal of Cancer, 115(11):1335–1342, October 2016. URL: http://dx.doi.org/10.1038/bjc.2016.326, doi:10.1038/bjc.2016.326. This article has 32 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2016.326)

[3. (Ferguson2005Human) Stephen S. Ferguson, Yuping Chen, Edward L. LeCluyse, Masahiko Negishi, and Joyce A. Goldstein. Human cyp2c8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane x receptor, glucocorticoid receptor, and hepatic nuclear factor 4α. Molecular Pharmacology, 68(3):747–757, June 2005. URL: http://dx.doi.org/10.1124/MOL.105.013169, doi:10.1124/mol.105.013169. This article has 257 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/MOL.105.013169)

[4. (Smith2008Role) Helen E. Smith, J.P. Jones, Thomas F. Kalhorn, Federico M. Farin, Patricia L. Stapleton, Connie L. Davis, James D. Perkins, David K. Blough, Mary F. Hebert, Kenneth E. Thummel, and Rheem A. Totah. Role of cytochrome p450 2c8 and 2j2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenetics and Genomics, 18(11):943–953, November 2008. URL: http://dx.doi.org/10.1097/fpc.0b013e32830e1e16, doi:10.1097/fpc.0b013e32830e1e16. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/fpc.0b013e32830e1e16)

[5. (Melet2004Analysis) Armelle Melet, Cristina Marques-Soares, Guillaume A. Schoch, Anne-Christine Macherey, Maryse Jaouen, Patrick M. Dansette, Marie-Agnès Sari, Eric F. Johnson, and Daniel Mansuy. Analysis of human cytochrome p450 2c8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry, 43(49):15379–15392, November 2004. URL: http://dx.doi.org/10.1021/bi0489309, doi:10.1021/bi0489309. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi0489309)

[6. (Jiang2010Structural) Hualin Jiang, Fangfang Zhong, Lu Sun, Weiyue Feng, Zhong-Xian Huang, and Xiangshi Tan. Structural and functional insights into polymorphic enzymes of cytochrome p450 2c8. Amino Acids, 40(4):1195–1204, September 2010. URL: http://dx.doi.org/10.1007/s00726-010-0743-8, doi:10.1007/s00726-010-0743-8. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00726-010-0743-8)

[7. (Dai2001Polymorphisms) Ding Dai, Darryl C. Zeldin, Joyce A. Blaisdell, Brian Chanas, Sherry J. Coulter, Burhan I. Ghanayem, and Joyce A. Goldstein. Polymorphisms in human cyp2c8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11(7):597–607, October 2001. URL: http://dx.doi.org/10.1097/00008571-200110000-00006, doi:10.1097/00008571-200110000-00006. This article has 388 citations.](https://doi.org/10.1097/00008571-200110000-00006)

[8. (Kaspera2010Cerivastatin) Rüdiger Kaspera, Suresh B. Naraharisetti, Bani Tamraz, Tariku Sahele, Matthew J. Cheesman, Pui-Yan Kwok, Kristin Marciante, Susan R. Heckbert, Bruce M. Psaty, and Rheem A. Totah. Cerivastatin in vitro metabolism by cyp2c8 variants found in patients experiencing rhabdomyolysis. Pharmacogenetics and Genomics, 20(10):619–629, October 2010. URL: http://dx.doi.org/10.1097/fpc.0b013e32833ecace, doi:10.1097/fpc.0b013e32833ecace. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/fpc.0b013e32833ecace)

[9. (Kandel2014Role) Sylvie E. Kandel and Jed N. Lampe. Role of protein–protein interactions in cytochrome p450-mediated drug metabolism and toxicity. Chemical Research in Toxicology, 27(9):1474–1486, August 2014. URL: http://dx.doi.org/10.1021/tx500203s, doi:10.1021/tx500203s. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/tx500203s)

[10. (Foti2016Comparison) Robert S. Foti, Philippe Diaz, and Dominique Douguet. Comparison of the ligand binding site of cyp2c8 with cyp26a1 and cyp26b1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(sup2):148–161, July 2016. URL: http://dx.doi.org/10.1080/14756366.2016.1193734, doi:10.1080/14756366.2016.1193734. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/14756366.2016.1193734)

[11. (Backman2015Role) Janne T. Backman, Anne M. Filppula, Mikko Niemi, and Pertti J. Neuvonen. Role of cytochrome p450 2c8 in drug metabolism and interactions. Pharmacological Reviews, 68(1):168–241, December 2015. URL: http://dx.doi.org/10.1124/pr.115.011411, doi:10.1124/pr.115.011411. This article has 173 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.115.011411)